In the study of CRC for cetuximab efficacy, EGFR inhibition was found in a part of patients with IGF2 overexpression, which could also weaken the efficacy of cetuximab in functional studies [31, 32]. This evidence concerns the gene IGF2 and colorectal carcinoma.